152 related articles for article (PubMed ID: 6669479)
21. Immunoprophylaxis of transplantable methylcholanthrene-induced murine fibrosarcomas by immunization with embryo cells expressing endogenous murine leukemia virus antigens.
Zbar B; Manohar V; Sugimoto T; Ashley MP; Kato Y; Rappaport P
Cancer Res; 1981 Nov; 41(11 Pt 1):4499-507. PubMed ID: 6272979
[TBL] [Abstract][Full Text] [Related]
22. Tumor suppression by pyran copolymer: correlation with production of cytotoxic macrophages.
Harmel RP; zbar B
J Natl Cancer Inst; 1975 Apr; 54(4):989-92. PubMed ID: 1127729
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
[TBL] [Abstract][Full Text] [Related]
24. [Antitumor effect of human recombinant interferon-alpha A/D in mice(I): Comparison between systemic and lesional treatment of meth-A sarcoma in BALB/c mice].
Nanjo M; Yoshie O; Aso H; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):505-9. PubMed ID: 4004283
[TBL] [Abstract][Full Text] [Related]
25. [Antitumor effect of Cepharanthin in the double grafted tumor system].
Ebina T; Ishikawa K; Murata K
Gan To Kagaku Ryoho; 1990 Jun; 17(6):1165-71. PubMed ID: 2350192
[TBL] [Abstract][Full Text] [Related]
26. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
Naruo KI; Hinuma S; Shiho O; Houkan T; Ootsu K; Tsukamoto K
Clin Exp Immunol; 1989 May; 76(2):278-83. PubMed ID: 2788049
[TBL] [Abstract][Full Text] [Related]
27. Changes in cellular components of spleen and lymph node cells and the effector cells responsible for Meth A tumor eradication induced by zinostatin stimalamer.
Masuda E; Maeda H
Cancer Res; 1996 Apr; 56(8):1868-73. PubMed ID: 8620506
[TBL] [Abstract][Full Text] [Related]
28. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
29. Kinetics of the plasmacellular reaction in the draining lymph node of mice bearing the BP-8 fibrosarcoma.
Stanislawski L; Stanislawski M
Cancer Res; 1976 Sep; 36(9 pt.1):3020-4. PubMed ID: 975071
[TBL] [Abstract][Full Text] [Related]
30. Vitamin A and tumor immunity.
Tomita Y; Himeno K; Nomoto K; Endo H; Hirohata T
Experientia; 1985 Jan; 41(1):92-3. PubMed ID: 3871403
[TBL] [Abstract][Full Text] [Related]
31. Properties of a M(r) 110,000 tumor rejection antigen of the chemically induced BALB/c Meth A sarcoma.
De Leo AB; Becker M; Lu L; Law LW
Cancer Res; 1993 Apr; 53(7):1602-7. PubMed ID: 7680955
[TBL] [Abstract][Full Text] [Related]
32. Specific desensitization of resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice.
Vaage J
Cancer Res; 1972 Feb; 32(2):193-9. PubMed ID: 5058179
[No Abstract] [Full Text] [Related]
33. Essential requirement of I-A region-identical host bone marrow or bone marrow-derived cells for tumor neutralization by primed L3T4+ T cells.
Ozawa H; Iwaguchi T; Kataoka T
J Immunol; 1987 Dec; 139(11):3896-901. PubMed ID: 2960743
[TBL] [Abstract][Full Text] [Related]
34. Growth promoting activity of PDGF, EGF and TGF-beta on highly metastatic subline of Meth A cells.
Niitsu Y; Koshida Y; Mahara K; Ishigaki S; Kogawa K; Watanabe N; Urushizaki Y; Kohgo Y; Urushizaki I
Immunopharmacol Immunotoxicol; 1988; 10(1):67-78. PubMed ID: 3258877
[TBL] [Abstract][Full Text] [Related]
35. In vivo and in vitro studies of the influence of the immune status of C3Hf-Bu mice on the effectiveness of local irradiation of a methylcholanthrene-induced fibrosarcoma.
Jurin M; Suit HD
Cancer Res; 1972 Oct; 32(10):2201-11. PubMed ID: 5080765
[No Abstract] [Full Text] [Related]
36. Specific depression of the antitumor cellular immune response with autologous tumor homogenate.
Paranjpe MS; Boone CW
Cancer Res; 1975 May; 35(5):1205-9. PubMed ID: 164281
[TBL] [Abstract][Full Text] [Related]
37. Oral administration of Chlorella vulgaris augments concomitant antitumor immunity.
Tanaka K; Tomita Y; Tsuruta M; Konishi F; Okuda M; Himeno K; Nomoto K
Immunopharmacol Immunotoxicol; 1990; 12(2):277-91. PubMed ID: 2229925
[TBL] [Abstract][Full Text] [Related]
38. [Reversion of the immunological eclipse and therapeutic vaccination against cancer in an experimental model].
Chiarella P; Vulcano M; Laborde E; Vermeulen M; Bruzzo J; Rearte B; Bustuoabad OD; Ruggiero RA
Medicina (B Aires); 2007; 67(1):44-8. PubMed ID: 17408020
[TBL] [Abstract][Full Text] [Related]
39. Host reactivity to a spontaneous tumor: generation of antitumor activity by lymph node cells following incubation in vitro.
Chandradasa KD; Blears J
Gan; 1984 May; 75(5):448-58. PubMed ID: 6745565
[TBL] [Abstract][Full Text] [Related]
40. Tumor immunity induction in inbred BALB/c mice by abrus agglutinin treated Meth-A fibrosarcoma cells.
Tung TC; Chang HC; Hsu YM; Hsu CT; Lin JY
Taiwan Yi Xue Hui Za Zhi; 1979 Jun; 78(6):605-7. PubMed ID: 290733
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
